Results 51 to 60 of about 4,121 (170)

De Novo Synthesis in Cancer Immunotherapy: Applications and Prospects

MedComm, Volume 7, Issue 7, July 2026.
De novo protein design creates novel structures for cancer immunotherapy, integrating rational design principles like modularity and specificity. Leveraging computational tools, it optimizes cytokine engineering, adoptive cellular therapy, and checkpoint regulation to enhance antitumor immunity.
Yang Jin, Yanfeng Wu, Jianhua Luo
wiley   +1 more source

Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?

Medicinal Research Reviews, Volume 46, Issue 4, Page 1111-1151, July 2026.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca, Mariana Feijó, Cátia V. Vaz, Bruno J. Pereira, Sandra Laurentino, Ana Palmeira‐de‐Oliveira, Sílvia Socorro   +6 more
wiley   +1 more source

Immunotoxin therapy: a promising frontier in targeted cancer treatment a review of clinical trials in hematological and solid tumors

Cancer Treatment and Research Communications
Background and objective: Background and objective: Cancer is a leading cause of death worldwide, creating a major socioeconomic burden. Despite advances in conventional therapies, mortality remains high, highlighting the need for more effective ...
Arash Abdi, Hamid Sedighian, Zoleikha Goleij, Mahdi Fasihi-Ramandi, Reza Kachuei, Abbas Ali Imani Fooladi   +5 more
doaj   +1 more source

Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH

Journal of Translational Medicine, 2023
Background Immunotoxins are antibody-toxin conjugates that bind to surface antigens and exert effective cytotoxic activity after internalization into tumor cells.
Xiaoyu Liu, Qingqing Tan, Jiaqi Wen, Xufei Wang, Gang Yang, Yuxiao Li, Ming Lu, Wei Ye, Anfeng Si, Sujuan Ma, Tong Ding, Luan Sun, Fang Liu, Mei Zhang, Tao Jiang, Wei Gao   +15 more
doaj   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, Volume 13, Issue 35, 24 June 2026.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins. [PDF]

PLoS ONE, 2016
The intersection of small molecular weight drugs and antibody-based therapeutics is rarely studied in large scale. Both types of agents are currently part of the cancer armamentarium.
Antonella Antignani, Lesley Mathews Griner, Rajarshi Guha, Nathan Simon, Matteo Pasetto, Jonathan Keller, Manjie Huang, Evan Angelus, Ira Pastan, Marc Ferrer, David J FitzGerald, Craig J Thomas   +11 more
doaj   +1 more source

Delivering Proteins and Enzymes to Solid Tumors Through the Development of Stimuli‐Responsive Nanocarriers

ChemNanoMat, Volume 12, Issue 6, June 2026.
Stimuli‐responsive strategies to achieve controlled release of protein‐based therapeutic agents into solid tumors. Proteins, enzymes, and peptides have long been recognized as valuable therapeutic agents, particularly in oncology. However, their complex chemical structures render them more sensitive than smaller chemotherapeutic drugs.
Guillermo Plaza‐Palomo, Diana Benita‐Donadios, Sandra Jiménez‐Falcao, Alejandro Baeza   +3 more
wiley   +1 more source

Targeted Diphtheria Toxin-Based Therapy: A Review Article

Frontiers in Microbiology, 2019
Cancer remains one of the leading causes of death worldwide. Conventional therapeutic strategies usually offer limited specificity, resulting in severe side effects and toxicity to normal tissues.
Fatemeh Shafiee, Marc G. Aucoin, Ali Jahanian-Najafabadi   +2 more
doaj   +1 more source

Edulitin 2, a Ribotoxin‐Like Protein From Boletus edulis That Triggers Apoptosis in Colon Cancer Cells While Preserving the Integrity of the Intestinal Microbiota

eFood, Volume 7, Issue 3, June 2026.
Edulitin 2 is a ribotoxin‐like protein exhibiting a potent antiproliferative activity towards Caco‐2 and HT29 cells by programmed cell death. However, edulitin 2 does not affect gut microbiota growth, despite damaging fungal ribosomes. ABSTRACT Porcini (Boletus edulis Bull.) are a reservoir of pharmacological biomolecules with health‐promoting ...
Massimo Bortolotti, Sara Ragucci, Federica Falà, Anella Saggese, Francesco Biscotti, Ylenia De Luca, Nicola Landi, Paolo V. Pedone, Andrea Bolognesi, Ezio Ricca, Letizia Polito, Antimo Di Maro   +11 more
wiley   +1 more source

Inclusion of a Furin Cleavage Site Enhances Antitumor Efficacy against Colorectal Cancer Cells of Ribotoxin α-Sarcin- or RNase T1-Based Immunotoxins

Toxins, 2019
Immunotoxins are chimeric molecules that combine the specificity of an antibody to recognize and bind tumor antigens with the potency of the enzymatic activity of a toxin, thus, promoting the death of target cells.
Javier Ruiz-de-la-Herrán, Jaime Tomé-Amat, Rodrigo Lázaro-Gorines, José G. Gavilanes, Javier Lacadena   +4 more
doaj   +1 more source